Evolve Private Wealth’s Quest Diagnostics DGX Stock Holding History

Evolve Private Wealth’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,079	Closed	-$212K	–	1059
2026 Q1	$212K	Buy	+1,079	New	+$210K	0.01%	918

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Evolve Private Wealth's DGX Position: Q2 2026 in Review

Evolve Private Wealth sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 1,079 shares — an estimated $212K sold.

Evolve Private Wealth first reported a position in DGX in Q1 2026 and held it in 1 quarter. The position peaked at $212K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Evolve Private Wealth reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
Evolve Private Wealth sold 1,079 Quest Diagnostics shares in Q2 2026, an estimated $212K.
Evolve Private Wealth first reported a position in Quest Diagnostics in Q1 2026 and held it in 1 quarter.
Evolve Private Wealth's Quest Diagnostics position peaked at $212K in Q1 2026.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.